Stilla Technologies completes €16 Million Series A

Novel digital PCR system

23-Nov-2018 - Stilla Technologies, provider of pioneering digital PCR solutions for high precision genetic analysis, announced today the successful completion of a Series A financing round of 16 million euros ($18 Million) led by Illumina Ventures, with participation from Kurma Partners, LBO France, BNP ...

PDC*line Pharma receives Advanced-Therapy Medicinal Product classification for its new class of therapeutic cancer vaccines

18-Jun-2015 - PDC*line Pharma, a clinical-stage biotech company, announces that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic Cells (PDC*line), was granted Advanced-Therapy Medicinal Product (ATMP) classification by the Committee for Advanced Therapies (CAT) of ...

VEXIM strengthens his management team

12-Jun-2015 - VEXIM announced the appointments of Gunther Peeters as VP Sales Europe & Global Marketing and Remco Maljers as VP Indirect Sales & Business Development, both effective in May 2015.With over 13 years of experience in the Healthcare Industry, Gunther Peeters, 35, started working as a Sales ...

Cipher Pharmaceuticals acquires INNOCUTIS Holdings

15-Apr-2015 - Onxeo S.A. announced Cipher Pharmaceuticals' acquisition of INNOCUTIS Holdings LLC, the licensee of Sitavig® in the USA. As a major step in the growth strategy of Cipher Pharmaceuticals, this acquisition provides Cipher with a commercial infrastructure and a talented sales team for the USA. "We ...

Adocia opens a subsidiary in the USA

09-Mar-2015 - Adocia announced the creation of a subsidiary in the USA, Adocia Incorporated, and the accompanying appointments of Simon Bruce, MD and Stephen Daly. Opening a US subsidiary is a key step in Adocia's strategy, the USA are currently the primary market for its productsTwo employees are already ...

Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag in primary liver cancer

26-Nov-2014 - Onxeo SA announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety monitoring of the Livatag® Phase III trial has once again unanimously recommended continuing the study without modification."Each new positive recommendation from our ...

Positive Phase II preliminary results of Validive for the prevention of Severe Oral Mucositis in Head and Neck cancer patients

Improved oral mucositis related symptoms and decreased adverse events related to radiotherapy

03-Nov-2014 - Onxeo S.A. announced positive preliminary top-line results from its Phase II clinical trial of Validive® (mucoadhesive buccal tablet MBT clonidine Lauriad®) for prevention of severe oral mucositis (OM).Oral mucositis is a radio/chemotherapy related condition occurring very frequently in patients ...

Miguel Sieler named C.E.O of Neovacs

21-Oct-2013 - NEOVACS annonced that Miguel Sieler, former Chairman and Chief Executive Officer of Bayer France has been named Chief Executive Officer of Neovacs, replacing Guy-Charles Fanneau De La Horie. Miguel Sieler will pursue the development of Neovacs and put a particular focus on the value of its ...

Généthon receives the 2012 Galien Prize for its Innovative Treatments in Gene Therapy

09-Oct-2012 - The 43rd Prix Galien recognized Généthon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of "Medicines destined for rare diseases - cell therapy and gene therapy." Created in 1990 by a patient association, the AFM-Téléthon, and 90% ...

Alain Schwenck becomes Director of Genethon Bioprod

09-Jul-2012 - Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. Mr. Schwenck is a seasoned expert in manufacturing of pharmaceutical products. He began ...